Rosuvastatin in Older Patients with Systolic Heart Failure
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins have theoretical risks in these patients. METHODS: A total of 5011 patients at least 60 years of age with New York Heart Association class II, III, or IV ischemic, systolic heart failure were randomly assigned to receive 10 mg of rosuvastatin or placebo per day. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary outcomes included death from any cause, any coronary event, death from cardiovascular causes, and the number of hospitalizations. RESULTS: As compared with the placebo group, patients in the rosuvastatin group had decreased levels of low-density lipoprotein cholesterol (difference between groups, 45.0%; P<0.001) and of high-sensitivity C-reactive protein (difference between groups, 37.1%; P<0.001). During a median follow-up of 32.8 months, the primary outcome occurred in 692 patients in the rosuvastatin group and 732 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.83 to 1.02; P=0.12), and 728 patients and 759 patients, respectively, died (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.31). There were no significant differences between the two groups in the coronary outcome or death from cardiovascular causes. In a prespecified secondary analysis, there were fewer hospitalizations for cardiovascular causes in the rosuvastatin group (2193) than in the placebo group (2564) (P<0.001). No excessive episodes of muscle-related or other adverse events occurred in the rosuvastatin group. CONCLUSIONS: Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations. The drug did not cause safety problems. (ClinicalTrials.gov number, NCT00206310.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The clinical benefit of adding ezetimibe was consistent across patient subgroups [299,444] and also led to a reduction of total CV events [445], stroke [446], and rehospitalizations [447].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [445]
In the citing paper
“The Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) and Gruppo Italiano per lo Studio della Sopravivenza nell'Infarto Miocardico-Effect of Rosuvastatin in Patients with Chronic Heart Failure (GISSI-HF) trials in patients with symptomatic HF did not demonstrate any benefit on CV mortality and non-fatal MI and stroke, in spite of a marked reduction of LDL-C and hs-CRP.36,39”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [36]
In the citing paper
“In two large RCTs 373,374 there was no benefit on hard endpoints, such as CV mortality and non-fatal MI and stroke, in spite of a decrease in hospitalizations 373,375 and a marked reduction of LDL-C and hs-CRP in patients with mainly systolic heart failure.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [373]
In the citing paper
“Trials of low‐dose anticoagulation, 4 PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, 5 as well as statins 2 , 6 in patients with HF have been disappointing to date”
From Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT (2022) · cites this paper as [2]
In the citing paper
“Patients with heart failure (HF) are at high risk for atherosclerotic cardiovascular disease (ASCVD), 1 , 2 as designated by professional society guidelines. 3”
From Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT (2022) · cites this paper as [2]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Self-citationSacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Hjalmarson, Å., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Wikstrand, J., El Allaf, D., Vítovec, J., Aldershvile, J., et al. (2000) · JAMA · doi:10.1001/jama.283.10.1295 · Cited by 1,399
Self-citationThe Role of Coenzyme Q10 in Statin-Associated Myopathy
Marcoff, L., & Thompson, P. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.049 · Cited by 537
The endotoxin-lipoprotein hypothesis
Rauchhaus, M., Coats, A. J., & Anker, S. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02690-8 · Cited by 533
The relationship between cholesterol and survival in patients with chronic heart failure
Rauchhaus, M., Clark, A. L., Doehner, W., Davos, C., Bolger, A., Sharma, R., Coats, A. J. S., & Anker, S. D. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.016 · Cited by 444
Inhalation of levomepromazine in severe acute asthma
Pedersen, J. E., Olsen, A., & Banning, A. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91755-8 · Cited by 390
Cited by
Items 601–700 of 1,000
Albuquerque, E. L., Fulco, U. L., Caetano, E. W. S., & Freire, V. N. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108774956.011 · Cited by 21
Hemodynamic correlates of nutritional indexes in heart failure
Horiuchi, Y., Tanimoto, S., Okuno, T., Aoki, J., Yahagi, K., Sato, Y., Tanaka, T., Koseki, K., Komiyama, K., Nakajima, H., et al. (2017) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.11.006 · Cited by 25
Huang, H., Ma, R., Liu, D., Liu, C., Ma, Y., Mai, W., & Dong, Y. (2012) · Disease Markers · doi:10.1155/2012/167143 · Cited by 22
Rosen, V. M., Taylor, D. C. A., Parekh, H., Pandya, A., Thompson, D., Kuznik, A., Waters, D. D., Drummond, M., & Weinstein, M. C. (2009) · PharmacoEconomics · doi:10.2165/11531440-000000000-00000 · Cited by 24
Statin Therapy and Clinical Outcomes in Heart Failure: A Propensity-Matched Analysis
Ouzounian, M., Tu, J. V., Austin, P. C., Chong, A. S., Liu, P. P., & Lee, D. S. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.10.026 · Cited by 22
Current perspectives on rosuvastatin
Tomlinson, B., & Hu (2013) · Integrated Blood Pressure Control · doi:10.2147/ibpc.s34814 · Cited by 26
Friedman, L. M., Furberg, C. D., & DeMets, D. L. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1586-3_6 · Cited by 24
Impact of statin therapy on patients with coronary heart disease and aortic aneurysm or dissection
Tazaki, J., Morimoto, T., Sakata, R., Okabayashi, H., Yamazaki, F., Nishiwaki, N., Mitsudo, K., & Kimura, T. (2014) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2014.03.280 · Cited by 21
Eschalier, R., Chenaf, C., Mulliez, A., Yalioua, A., Clerfond, G., Authier, N., Vorilhon, C., Citron, B., Pereira, B., Jean, F., et al. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6572-y · Cited by 22
“On the contrary, dedicated studies (CORONA [32] and GISSI-HF [33]) failed to show the benefit of statins use in chronic HF patients (>60 year’s old in CORONA and whatever the LV ejection fraction in GISSI-HF).”
ResultHo, J. E., Waters, D. D., Kean, A. J., Wilson, D. J., DeMicco, D. A., Breazna, A., Wun, C., DEEDWANIA, P. C., & Khush, K. K. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.02.019 · Cited by 21
Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis
Borghi, C., & Levy, B. I. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.11.015 · Cited by 21
Low‐Density Lipoprotein Levels in Patients With Acute Heart Failure
Kahn, M. R., Kosmas, C. E., Wagman, G., Serrao, G. W., Fallahi, A., Grady, K. M., & Vittorio, T. J. (2012) · Congestive Heart Failure · doi:10.1111/chf.12006 · Cited by 22
Horwich, T. B., Middlekauff, H. R., MacLellan, W. R., & Fonarow, G. C. (2011) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2011.07.008 · Cited by 21
Effects of Pitavastatin on Pressure Overload-Induced Heart Failure in Mice
Kameda, Y., Hasegawa, H., Kubota, A., Tadokoro, H., Kobayashi, Y., Komuro, I., & Takano, H. (2012) · Circulation Journal · doi:10.1253/circj.cj-11-1114 · Cited by 21
Ueland, T., Nymo, S. H., Latini, R., McMurray, J. J. V., KJEKSHUS, J. K., Yndestad, A., Fucili, A., Grosu, A., Masson, S., Maggioni, A. P., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft031 · Cited by 21
Self-citationEfeito anti-inflamatório do treinamento físico na insuficiência cardíaca: papel do TNF-α e da IL-10
Batista, M., Lopes, R., Seelaender, M., & Lopes, A. (2009) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2009001200021 · Cited by 10
Statins and dilated cardiomyopathy: do we have enough data?
Bielecka-Dabrowa, A. M., Mikhailidis, D. P., Hannam, S., Aronow, W. S., Rysz, J., & Banach, M. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.550570 · Cited by 22
López, R. Q., Alegría, J. G., Escalante, M. D. M., Trujillo‐Santos, J., Villena-Ruiz, M. A., & Milla, E. P. (2011) · Medicina Clínica · doi:10.1016/j.medcli.2011.03.031 · Cited by 22
Statins and new-onset diabetes—the important questions
Preiss, D., & Sattar, N. A. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.15 · Cited by 25
Tousoulis, D., Andreou, I., Tentolouris, C. A., Antoniades, C. A., Παπαγεωργίου, Ν., Gounari, P., Kotrogiannis, I., Miliou, A., Charakida, M., Trikas, A. G., et al. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2009.05.051 · Cited by 21
Recent insights on chronic heart failure, cachexia and nutrition
Miján-de-la-Torre, A. (2009) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32832a2171 · Cited by 22
Traditional and Novel Approaches to Management of Heart Failure: Successes and Failures
Anand, I. S., & Florea, V. G. (2008) · Cardiology Clinics · doi:10.1016/j.ccl.2008.01.001 · Cited by 23
Tratamiento de los factores de riesgo vascular en el paciente mayor de 80 años
Gómez‐Huelgas, R., Martínez‐Sellés, M., Formiga, F., Sánchez, J. J. A., Camafort, M., Galve, E., Gil, P., & Lobos, J. M. (2014) · Medicina Clínica · doi:10.1016/j.medcli.2014.04.001 · Cited by 26
Doğan, S., Kastelein, J. J. P., Grobbee, D. E., & Bots, M. L. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.8623 · Cited by 21
Xu, M.-W., Yuan, G., & Wei, F. (2010) · Archives of Medical Science · doi:10.5114/aoms.2010.19293 · Cited by 23
Sadowitz, B. D., Seymour, K. A., Costanza, M. J., & Gahtan, V. (2010) · Vascular and Endovascular Surgery · doi:10.1177/1538574410363833 · Cited by 27
“Treatment with rosuvastatin did not show any benefit with respect to the primary outcomes, specifically death from cardiovascular causes; nonfatal myocardial infarction; and nonfatal stroke.(40) The GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico-Heart Failure) trial included 4574 p…”
BackgroundMethodInhibition of the mevalonate pathway improves myocardial fibrosis
Xu, H., Shen, Y. X., Liang, C., Wang, H., Huang, J., Xue, P., & Luo, M. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9655 · Cited by 19
Signaling Pathways in Inflammation and Cardiovascular Diseases: An Update of Therapeutic Strategies
Cucu, I. (2022) · Immuno · doi:10.3390/immuno2040039 · Cited by 24
Michos, E. D., Long, S., Blaha, M. J., & Blumenthal, R. S. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s8101 · Cited by 20
Lipid-lowering agents and new onset diabetes mellitus
Athyros, V. G., Τζιόμαλος, Κ., Karagiannis, A. I., & Mikhailidis, D. P. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.489553 · Cited by 21
Actualización en cardiología geriátrica
Díaz-Castro, Ó., Datino, T., López‐Palop, R., & Martínez‐Sellés, M. (2011) · Revista Española de Cardiología · doi:10.1016/s0300-8932(11)70002-1 · Cited by 22
Analysing falls in coronary heart disease mortality in the West Bank between 1998 and 2009
Abu-Rmeileh, N. M. E., Shoaibi, A., O’Flaherty, M., Capewell, S., & Husseini, A. S. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001061 · Cited by 24
de Peuter, O. R., Lip, G. Y. H., Souverein, P. C., Klungel, O. H., de Boer, A., Buller, H. R., & Kamphuisen, P. W. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq228 · Cited by 20
Predicting therapeutic response in patients with heart failure: the story of C-reactive protein
Huynh, K., Tassell, B. W. V., & Chow, S. L. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1000307 · Cited by 20
Hasenfuss, G. P., Anker, S. D., Bauersachs, J. K., Böhm, M., Hoppe, U. C., Pieske, B. M., von Scheidt, W., & Wachter, R. (2013) · Der Kardiologe · doi:10.1007/s12181-013-0491-6 · Cited by 28
Self-citationTokuhisa, H., Murai, H., Okabe, Y., Hamaoka, T., Sugimoto, H., Mukai, Y., Inoue, O., Takashima, S., Kato, T., Usui, S., et al. (2018) · Autonomic Neuroscience · doi:10.1016/j.autneu.2018.04.006 · Cited by 20
Hansen, M., Hróbjartsson, A., Pottegård, A., Damkier, P., Larsen, K. S., Madsen, K. G., Christensen, R. D., Kristensen, M. E. L., Christensen, P. M., & Hallas, J. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05024-4 · Cited by 25
Reddy, Y. N. V., Borlaug, B. A., O’Connor, C. M., & Gersh, B. J. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz364 · Cited by 24
Diabetic cardiomyopathy: ongoing controversies in 2012
Seferovic, P. M., Milinković, I., Ristić, A. D., Mitrović, J., Lalic, K. S., Jotić, A., Kanjuh, V., Lalic, N. M., & Maisch, B. (2012) · Herz · doi:10.1007/s00059-012-3720-z · Cited by 21
Bronzwaer, J. G. F., & Paulus, W. J. (2009) · Current Heart Failure Reports · doi:10.1007/s11897-009-0038-0 · Cited by 28
“This positive outcome of statin therapy in DHF patients contrasts with the recently reported neutral outcome of statin therapy in SHF patients observed in the CORONA trial [ 35 ].”
ResultShirakabe, A., Asai, K., Hata, N., Yokoyama, S., Shinada, T., Kobayashi, N., Tomita, K., Tsurumi, M., Matsushita, M., & Mizuno, K. (2012) · Journal of Cardiology · doi:10.1016/j.jjcc.2012.01.009 · Cited by 20
Lorgelly, P. K., Briggs, A. H., Wedel, H., Dunselman, P., Hjalmarson, Å. C., KJEKSHUS, J. K., Waagstein, F., Wikstrand, J., Jánosi, A., van Veldhuisen, D. J., et al. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp172 · Cited by 20
Self-citationBermejo, J., Segovia, J., & Alfonso, F. (2008) · Revista Española de Cardiología · doi:10.1157/13116214 · Cited by 20
Cardiac fibrosis: emerging agents in preclinical and clinical development
Spoladore, R., Falasconi, G., Fiore, G., Maio, S. D., Preda, A., Slavich, M., Margonato, A., & Fragasso, G. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1868432 · Cited by 21
Heart Failure and Diabetes Mellitus: Dangerous Liaisons
Lee, H. (2022) · International Journal of Heart Failure · doi:10.36628/ijhf.2022.0022 · Cited by 23
Impact of Statin Therapy in Heart Failure Patients
Anderson, J. L., May, H. T., Le, V. T., Muhlestein, J. B., Horne, B. D., Bair, T. L., Knight, S., & Knowlton, K. U. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100385 · Cited by 28
Medication Management of Chronic Heart Failure in Older Adults
Alagiakrishnan, K., Banach, M., Jones, L. G., Ahmed, A., & Aronow, W. S. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0105-9 · Cited by 22
Rosuvastatin: A Review of its Effect on Atherosclerosis
Keating, G. M., & Robinson, D. M. (2008) · American Journal of Cardiovascular Drugs · doi:10.1007/bf03256589 · Cited by 20
Virani, S. S., Nambi, V., Lee, V., Elayda, M. A., Reul, R. M., Wilson, J. M., & Ballantyne, C. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.06.055 · Cited by 19
Heart failure therapy in patients with coronary artery disease
Taylor, C. J., & Hobbs, R. F. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.01.009 · Cited by 22
Heart failure with preserved ejection fraction
ElGuindy, A. M., & Yacoub, M. H. (2012) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2012.10 · Cited by 23
Diabetogenic Effect of Statins: A Double-Edged Sword?
Yoon, J. S., & Lee, H. W. (2013) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2013.37.6.415 · Cited by 22
Ji, M. S., Jeong, M. H., Ahn, Y. K., Kim, S. H., Kim, Y. J., Chae, S. C., Hong, T. J., Seong, I. W., Chae, J. K., Kim, C. J., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.082 · Cited by 21
Campbell, R. T., Willox, G., Jhund, P. S., Hawkins, N. M., Huang, F., Petrie, M. C., & McMurray, J. J. V. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002842 · Cited by 23
Self-citationStatin Adherence and Mortality in Patients Aged 80 Years and Older After Acute Myocardial Infarction
Phan, D. Q., Duan, L., Lam, B., Hekimian, A., Wee, D., Zadegan, R., & Lee, M. S. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16037 · Cited by 21
Statin use and high-dose statin use after ischemic stroke in the UK: a retrospective cohort study
Yang, Z., Edwards, D., Massou, E., Saunders, C. L., Brayne, C., & Mant, J. (2019) · Clinical Epidemiology · doi:10.2147/clep.s201983 · Cited by 17
Lipid-modifying therapy in chronic kidney disease: Pathophysiological and clinical considerations
Heine, G. H., Eller, K., Stadler, J. T., Rogacev, K. S., & Marsche, G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107459 · Cited by 20
Li, M., Zheng, C., Kawada, T., Inagaki, M., Uemura, K., Akiyama, T., & Sugimachi, M. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07062-1 · Cited by 19
HDL Composition, Heart Failure, and Its Comorbidities
Diab, A., Ripoll, C. V., Guo, Z., & Javaheri, A. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.846990 · Cited by 24
Suzuki, T., Nozawa, T., Sobajima, M., Igarashi, N., Matsuki, A., Fujii, N., & Inoue, H. (2008) · International Heart Journal · doi:10.1536/ihj.49.423 · Cited by 19
Rosuvastatin calcium in acute coronary syndromes
Aggarwal, R. K., & Showkathali, R. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.789860 · Cited by 20
Hypercholesterolemia and Myocardial function evaluated via Tissue Doppler Imaging
Rubinstein, J., Pelosi, A., Vedre, A., Kotaru, P., & Abela, G. S. (2009) · Cardiovascular Ultrasound · doi:10.1186/1476-7120-7-56 · Cited by 19
Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
Ling, H., Henry, C., & Ra, L. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s82387 · Cited by 20
Michos, E. D., Narla, V., Blaha, M. J., & Blumenthal, R. S. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s6412 · Cited by 19
Heart Failure With Preserved Ejection Fraction: Prevention and Management
Cilia, L., Saeed, A., Ganga, H. V., & Wu, W.-C. (2019) · American Journal of Lifestyle Medicine · doi:10.1177/1559827617695219 · Cited by 18
deFilippi, C. R., Alemayehu, W. G., Voors, A. A., Kaye, D. M., Blaustein, R. O., Butler, J., Ezekowitz, J. A., Hernandez, A. F., Lam, C. S. P., Roessig, L., et al. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.12.013 · Cited by 18
Herrmann, R., Sandek, A., von Haehling, S., Doehner, W., Schmidt, H. B., Anker, S. D., & Rauchhaus, M. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.10.028 · Cited by 20
“As recently published, statin therapy (rosuvastatin) did not reduce all-cause and cardiovascular mortality in a randomized, controlled clinical trial [32].”
BackgroundIzzo, R., SIMONE, G. D., Trimarco, V., Giudice, R., Marco, M. D., Renzo, G. D., LUCA, N. D., & Trimarco, B. (2013) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2012.11.002 · Cited by 21
Effect of selenium and Q10 on the cardiac biomarker NT-proBNP
Johansson, P., Dahlström, Ö., Dahlström, U., & Alehagen, U. (2013) · Scandinavian Cardiovascular Journal · doi:10.3109/14017431.2013.820838 · Cited by 19
Merkaš, I. S., Slišković, A. M., & Lakušić, N. (2021) · World Journal of Cardiology · doi:10.4330/wjc.v13.i7.183 · Cited by 23
Liao, Y., Hsieh, Y., Hung, C.-Y., Huang, J., Lin, C., Wang, K., & Wu, T. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.036 · Cited by 18
“[2] Kogias JS, Papadakis EX, Tsatiris CG, et al.”
BackgroundJia, X., Rifai, M. A., Birnbaum, Y., Smith, S. C., & Virani, S. S. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0784-8 · Cited by 19
Statin-Associated Cardiomyopathy Responds to Statin Withdrawal and Administration of Coenzyme Q 10
Langsjoen, P. H., Langsjoen, J., Langsjoen, A. M., & Rosenfeldt, F. (2019) · The Permanente Journal · doi:10.7812/tpp/18.257 · Cited by 22
“Total cholesterol, mg/dL 30 180 (165-194) 242 (225-259) 62 (45-79) < 0.”
Crosier, R., Austin, P. C., Ko, D. T., Lawler, P. R., Stukel, T. A., Farkouh, M. E., Wang, X., Spertus, J. A., Ross, H. J., & Lee, D. S. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.10.017 · Cited by 16
Chang, Y., Hsieh, M., Wang, C.-Y., Lin, K.-C., & Lee, Y.-J. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.157 · Cited by 22
Predictive Value of Endostatin in Chronic Heart Failure Patients with Poor Kidney Function
Ueland, T., Aukrust, P., Nymo, S. H., KJEKSHUS, J. K., McMurray, J. J. V., Wikstrand, J., Wienhues‐Thelen, U., Block, D., Zaugg, C. E., & Gullestad, L. L. (2014) · Cardiology · doi:10.1159/000368220 · Cited by 17
Self-citationStein, E. A., Vidt, D. G., Shepherd, J., Cain, V. A., Anzalone, D. A., & Cressman, M. D. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.12.011 · Cited by 17
Total Lipid Management and Cardiovascular Disease in the Dyslipidemia International Study
Ferrières, J., Amber, V., Crisan, O., Chazelle, F., Jünger, C., & Wood, D. (2013) · Cardiology · doi:10.1159/000348859 · Cited by 18
National Drug Formulary review of statin therapeutic group using the multiattribute scoring tool
Ramli, A., Aljunid, S. M., Sulong, S., & Yusof, F. A. M. (2013) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s52078 · Cited by 17
Charland, S. L., & Malone, D. C. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903484802 · Cited by 18
Li, J., Becher, P. M., Blankenberg, S., & Westermann, D. (2013) · Cardiology Research and Practice · doi:10.1155/2013/130724 · Cited by 19
Impact of statin use on heart failure mortality
Thambidorai, S. K., Deshmukh, A. R., Walters, R. W., Turner, P. D., Monaghan, M. S., Mooss, A. N., Hunter, C. B., Esterbrooks, D. J., & Mohiuddin, S. M. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.08.016 · Cited by 17
Soko, N. D., Masimirembwa, C. M., & Dandara, C. (2016) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2016.0114 · Cited by 20
Oikawa, T., Sakata, Y., Nochioka, K., Miura, M., Tsuji, K., Onose, T., Abe, R., Kasahara, S., Sato, M., Shiroto, T., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007524 · Cited by 20
Kim, Y. H., Her, A., Jeong, M. H., Kim, B., Shin, D., Kim, J., Ko, Y., Choi, D., Hong, M., & Jang, Y. (2018) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.27985 · Cited by 17
“However, the majority of the previous studies did not focus on the effect of statin therapy in patients with or without dyslipidemia especially the AMI milieu.(11,12) At present, first-generation drug-eluting stents (DES) were nearly replaced by second-generation DES in routine daily PCI.”
BackgroundResultLuca, L. D. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07027-4 · Cited by 22
Role of drugs and devices in patients at risk of sudden cardiac death
Boriani, G., Diemberger, I., Valzania, C., Biffi, M., Martignani, C., Raschi, E., Mantovani, V., Ziacchi, M., Bertini, M., Ponti, F. D., et al. (2010) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2010.00853.x · Cited by 17
Aortic stenosis and lipids: does intervention work?
Wierzbicki, A. S., Viljoen, A., & Chambers, J. B. (2010) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283393c9b · Cited by 19
Sharma, A., & Ezekowitz, J. A. (2013) · Current Heart Failure Reports · doi:10.1007/s11897-013-0152-x · Cited by 17
Statins for people with diabetes
Cheung, B. M. Y. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60081-1 · Cited by 17
Statin therapy in the prevention and treatment of atrial fibrillation
Lee, Y. L., Blaha, M. J., & Jones, S. R. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.11.002 · Cited by 17
Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?
Fabbri, G., & Maggioni, A. P. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0025-6 · Cited by 20
Drug Therapy of Heart Failure: An Immunologic View
Desoky, E. S. E. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181d169db · Cited by 18
Using Omics to Identify Novel Therapeutic Targets in Heart Failure
Lteif, C., Huang, Y., Guerra, L. A., Gawronski, B. E., & Duarte, J. D. (2024) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.123.004398 · Cited by 22
Rørth, R., Dewan, P., Kristensen, S. L., Jhund, P. S., Petrie, M. C., Køber, L., & McMurray, J. J. V. (2019) · Clinical Research in Cardiology · doi:10.1007/s00392-019-01415-z · Cited by 17
Self-citationZhu, X., Wang, Z., Ferrari, M. W., Ferrari‐Kuehne, K., Bulter, J., Xiu-ying, X., Zhou, Q., Zhang, Y., & Zhang, J. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13597 · Cited by 17
Chunawala, Z. S., Qamar, A., Arora, S., Pandey, A., Fudim, M., Vaduganathan, M., Bhatt, D. L., Mentz, R. J., & Caughey, M. C. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.01.002 · Cited by 17
Gouni‐Berthold, I., Schwarz, J., & Berthold, H. K. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01053-3 · Cited by 19
Predictive value of remnant cholesterol level for all-cause mortality in heart failure patients
Zhao, L., Zhao, X., Tian, P., Liang, L., Huang, B., Huang, L., Feng, J., Zhang, Y., & Zhang, J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1063562 · Cited by 16
Long-Term Outcomes of Early Coronary Artery Disease Testing After New-Onset Heart Failure
Zheng, J., Heidenreich, P. A., Kohsaka, S., Fearon, W. F., & Sandhu, A. T. (2023) · Circulation Heart Failure · doi:10.1161/circheartfailure.122.010426 · Cited by 16
Metadata
- Authors
- Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., Gullestad, L., Hjalmarson, Å., Hradec, J., Jánosi, A., Kamenský, G., Komajda, M., Korewicki, J., Kuusi, T., Mach, F., Mareev, V., McMurray, J. J. V., Ranjith, N., Schaufelberger, M., Vanhaecke, J., van Veldhuisen, D. J., Waagstein, F., Wedel, H., & Wikstrand, J.
- Affiliations
- Oslo University Hospital (NO)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-29
- Volume
- 357
- Issue
- 22
- Pages
- 2248-2261
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2126452437
- Cited by
- 1,487
- References
- 27
- Citations by year
- 2026: 24 · 2025: 27 · 2024: 41 · 2023: 43 · 2022: 62 · 2021: 46 · 2020: 63 · 2019: 72 · 2018: 53 · 2017: 75 · 2016: 73 · 2015: 89 · 2014: 96 · 2013: 109 · 2012: 96
- FWCI
- 140.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.scopus.com
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- rosuvastatin, heart failure with reduced ejection fraction, elderly patients, statins, cardiovascular mortality, cardiovascular hospitalization, LDL cholesterol, high-sensitivity C-reactive protein, statin safety, myocardial infarction, stroke
- MeSH terms
- Rosuvastatin Calcium, Aged, Cardiovascular Diseases, Female, Fluorobenzenes, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Pyrimidines, Sulfonamides, Systole, Proportional Hazards Models, Single-Blind Method, Treatment Outcome, Myocardial Ischemia, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.